Non-clear cell renal cell carcinoma
Jump to navigation
Jump to search
Section editor transclusions
Are you looking for a regimen but can't find it here? It is possible that we've moved it to the historical regimens page. For placebo or observational studies in this condition, please visit this page. If you still can't find it, please let us know so we can add it!
There are several related dedicated pages:
- General RCC page: Renal cell carcinoma
- Histology-specific:
- Biomarker-specific:
3 regimens on this page
3 variants on this page
|
Metastatic disease, first-line
Everolimus monotherapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Tannir et al. 2015 (ESPN) | 2010-2013 | Randomized Phase 2 (E-switch-ic) | Sunitinib | Did not meet primary endpoint of PFS |
| Armstrong et al. 2016 (ASPENRCC) | 2010-2013 | Randomized Phase 2 (E-switch-ic) | Sunitinib | Might have inferior PFS |
Note: ASPEN should not be confused with the trial by the same name in Waldenström macroglobulinemia.
Targeted therapy
- Everolimus (Afinitor) 10 mg PO once per day
- Dose can be reduced to 5 mg PO once per day or every other day if needed based on tolerability
Continued indefinitely
References
- ESPN: Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, Rao P, Sircar K, Karam JA, McDermott DF, Wood CG, Choueiri TK. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol. 2016 May;69(5):866-74. Epub 2015 Nov 26. link to original article link to PMC article contains verified protocol PubMed NCT01185366
- ASPEN: Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, George DJ. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016 Mar;17(3):378-88. Epub 2016 Jan 13. link to original article PubMed NCT01108445
Sunitinib monotherapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Tannir et al. 2015 (ESPN) | 2010-2013 | Randomized Phase 2 (E-switch-ic) | Everolimus | Did not meet primary endpoint of PFS |
| Armstrong et al. 2016 (ASPENRCC) | 2010-2013 | Randomized Phase 2 (E-switch-ic) | Everolimus | Might have superior PFS |
ASPEN should not be confused with the trial by the same name in Waldenström macroglobulinemia.
Targeted therapy
- Sunitinib (Sutent) 50 mg PO once per day on days 1 to 28
- Per some references, dose may be decreased to 37.5 mg or 25 mg PO once per day depending on tolerability
42-day cycles
References
- ESPN: Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, Rao P, Sircar K, Karam JA, McDermott DF, Wood CG, Choueiri TK. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol. 2016 May;69(5):866-74. Epub 2015 Nov 26. link to original article link to PMC article contains verified protocol PubMed NCT01185366
- ASPEN: Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, George DJ. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016 Mar;17(3):378-88. Epub 2016 Jan 13. link to original article PubMed NCT01108445